Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joseph Paul Eder

Showing results (1-10 of 27) with videos related to

Pageof 3
Sort By:
JCO Precision Oncology|June 8, 2022
Reply to E. Rosenbaum et alJoseph Paul Eder
Expert Opinion on Investigational Drugs|June 14, 2008
Therapeutic potential of novel selective-spectrum kinase inhibitors in oncologyPatricia M Lorusso, Joseph Paul Eder
Oncology (Williston Park, N.Y.)|November 13, 2014
Prospects for targeting PD-1 and PD-L1 in various tumor typesJoseph W Kim, Joseph Paul Eder
Immunotherapy|June 29, 2016
Targeting KIT on innate immune cells to enhance the antitumor activity of checkpoint inhibitorsMaximilian Stahl, Richard Gedrich, Ronald Peck, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 26, 2009
Novel therapeutic inhibitors of the c-Met signaling pathway in cancerJoseph Paul Eder, George F Vande Woude, Scott A Boerner, et al.
Cancer Investigation|July 28, 2023
Platinum Sensitivity in <i>IDH1/2</i> Mutated Intrahepatic Cholangiocarcinoma: Not All "BRCAness" Is Created EqualDeborah Blythe Doroshow, Wei Wei, Meenakshi Mehrotra, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 4, 2005
Phase I trial of the matrix metalloproteinase inhibitor marimastat combined with carboplatin and paclitaxel in patients with advanced non-small cell lung cancerJohn R Goffin, Ian C Anderson, Jeffrey G Supko, et al.
The Lancet. Oncology|June 2, 2016
Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trialTanguy Y Seiwert, Barbara Burtness, Ranee Mehra, et al.
JCO Precision Oncology|February 27, 2024
Circulating Tumor DNA Dynamics Fail to Predict Efficacy of Poly(ADP-ribose) Polymerase/VEGFR Inhibition in Patients With Heavily Pretreated Advanced Solid TumorsYiduo Hu, Azeet Narayan, Yunshan Xu, et al.
JCO Precision Oncology|February 1, 2022
Tissue/Site-Agnostic Study of Ribociclib for Tumors With Cyclin D-CDK4/6 Pathway Genomic Alterations: A Phase II, Open-Label, Single-Arm Basket StudyJulio Peguero, Davendra P S Sohal, Bert H O'Neil, et al.
Pageof 3

Showing results (1-10 of 27) with videos related to

Sort By:
Pageof 3
JCO Precision Oncology|June 8, 2022
Reply to E. Rosenbaum et alJoseph Paul Eder
Expert Opinion on Investigational Drugs|June 14, 2008
Therapeutic potential of novel selective-spectrum kinase inhibitors in oncologyPatricia M Lorusso, Joseph Paul Eder
Oncology (Williston Park, N.Y.)|November 13, 2014
Prospects for targeting PD-1 and PD-L1 in various tumor typesJoseph W Kim, Joseph Paul Eder
Immunotherapy|June 29, 2016
Targeting KIT on innate immune cells to enhance the antitumor activity of checkpoint inhibitorsMaximilian Stahl, Richard Gedrich, Ronald Peck, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 26, 2009
Novel therapeutic inhibitors of the c-Met signaling pathway in cancerJoseph Paul Eder, George F Vande Woude, Scott A Boerner, et al.
Cancer Investigation|July 28, 2023
Platinum Sensitivity in <i>IDH1/2</i> Mutated Intrahepatic Cholangiocarcinoma: Not All "BRCAness" Is Created EqualDeborah Blythe Doroshow, Wei Wei, Meenakshi Mehrotra, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 4, 2005
Phase I trial of the matrix metalloproteinase inhibitor marimastat combined with carboplatin and paclitaxel in patients with advanced non-small cell lung cancerJohn R Goffin, Ian C Anderson, Jeffrey G Supko, et al.
The Lancet. Oncology|June 2, 2016
Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trialTanguy Y Seiwert, Barbara Burtness, Ranee Mehra, et al.
JCO Precision Oncology|February 27, 2024
Circulating Tumor DNA Dynamics Fail to Predict Efficacy of Poly(ADP-ribose) Polymerase/VEGFR Inhibition in Patients With Heavily Pretreated Advanced Solid TumorsYiduo Hu, Azeet Narayan, Yunshan Xu, et al.
JCO Precision Oncology|February 1, 2022
Tissue/Site-Agnostic Study of Ribociclib for Tumors With Cyclin D-CDK4/6 Pathway Genomic Alterations: A Phase II, Open-Label, Single-Arm Basket StudyJulio Peguero, Davendra P S Sohal, Bert H O'Neil, et al.
Pageof 3